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Inflammation is a response to infections or tissue injuries. Inflammation was once defined by clinical signs, later by the presence of
leukocytes, and nowadays by expression of “proinflammatory” cytokines and chemokines. But leukocytes and cytokines often have
rather anti-inflammatory, proregenerative, and homeostatic effects. Is there a need to redefine “inflammation”? In this review, we
discuss the functions of “inflammatory” mediators/regulators of the innate immune system that determine tissue environments to
fulfill the need of the tissue while regaining homeostasis after injury.
1. Introduction
Inflammation is one of the major danger control programs of
tissue pathology conserved during evolution till date with a
major aim to resolve the infection, repair the tissue damage,
and regain the state of tissue homeostasis [1, 2]. It is a
highly complex but still a very well-coordinated process,
classically triggered by infection or tissue injury. Historically,
“inflammation”was initially defined based on the clinical rep-
resentations by Hippocrates as calor, rubor, tumor, and dolor
[3].This definition was challenged by the discovery of micro-
scope in the 19th century, and the microscopic presence of
leukocytes at the site of infection or injury was called “inflam-
mation” since then [4]. However, this simplistic definition
of “inflammation” does no longer hold true in the 21st
century mainly because of the advancements in immunology
and leukocyte biology in the last decade. We now know
that leukocytes present numerous immunoregulatory pheno-
types, for example,M2macrophages, regulatory T andB cells,
and fibrocytes, having anti-inflammatory functions. This
implies that the presence of leukocytes observed by pathol-
ogists at sites of infection or injury does not necessarily indi-
cate “inflammation,” at least without further characterizing
their functional phenotypes. As such, we now define “inflam-
mation” based on the presence of proinflammatory leukocyte
phenotypes along with the expression of proinflammatory
cytokines.
A successful inflammatory response eliminates the trig-
ger followed by a resolution of inflammation and tissue
repair by numerous anti-inflammatory cytokines as well as
lipid mediators [5–8]. However, a persistent injurious trigger
shifts the homeostatic set points fetching several changes in
the initial inflammatory process (chronic inflammation), for
example, replacement of neutrophils with macrophages and
T cells and subsequent formation of granulomata or tertiary
lymphoid tissues. In case these cellular effectors fail to control
the injurious trigger, collateral tissue damage occurs [9–11].
Moreover, chronic inflammation can also arise as a result
of autoimmune responses [9, 11]. Regardless of the cause,
inflammation supposedly evolved to restore homeostasis. In
this review, we discuss how different mediators of inflamma-
tion, in particular, of the innate immune system, set tissue
environments to resolve inflammation and reinforce tissue
repair, by promoting either regeneration or fibrosis in order to
regain homeostasis after injury (Figure 1).
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2. Resolution of Inflammation
An acute inflammatory response is followed by the resolution
phase. The processes to return to tissue homeostasis, that
is, catabasis [12], are governed by innate immune cells
and specific mediators produced by them. These processes
involve neutrophil apoptosis and their phagocytic removal
via efferocytosis, clearance of proinflammatory dead cells
and cytokines, and recruitment or phenotype switching of
macrophages to anti-inflammatory phenotype [13]. Neutro-
phil-derived microparticles can also trigger the resolution of
inflammation [13, 14]. Factors thatmediate resolution include
interleukin- (IL-) 10 andTGF-𝛽, as well as lipidmediators, for
example, lipoxins, resolvins, protectins, and maresins, collec-
tively termed as specialized proresolving mediators (SPMs)
[6, 15]. Within minutes after tissue injury prostaglandin
and leukotriene synthesis from arachidonic acid metabolism
occurs at the site of inflammation leading to the recruit-
ment of neutrophils as a result of the chemotactic gradient,
increased blood flow, and vascular permeability [16]. This is
often followed by the class switching of lipid mediators,
in which arachidonic acid metabolism switches from the
production of leukotrienes to anti-inflammatory lipoxins,
thus sending the “stop” signal to neutrophils recruitment
and begins the end of the acute inflammatory response [17].
Lipoxins and resolvins stimulate the nonphlogistic phagocy-
tosis of apoptotic neutrophils by monocyte-derived macro-
phages [18]. SPMs counterregulate the proinflammatory
mediators and thus reduce the magnitude and duration of
inflammation and tissue regeneration [12, 19].
Apart from limiting neutrophil recruitment, SPMs also
help to increase natural killer (NK) cells mediated neutrophil
apoptosis and subsequent efferocytosis by macrophages
[20]. They potently inhibit the release of proinflammatory
cytokines from the group 2 innate lymphoid cells (ILCs)
[20] and increase IL-10 production by macrophages as well
as induce M1 to M2 macrophage phenotype switch [21]. In
addition to SPMs, the complement system also contributes to
the resolution of inflammation by enhancing efferocytosis of
apoptotic cells [22, 23].The continuous phagocytosis of apop-
totic cells, regulated by the mitochondrial membrane protein
Ucp2 [24], stimulates monocytes to release IL-10 and TGF-
𝛽 further promotes the switch toward an anti-inflammatory
M2macrophage phenotype [25, 26]. Recently, resolvinD1 has
been demonstrated to triggerGPR32 to polarizemacrophages
toward the proresolving M2 phenotype [27]. Furthermore,
IL-10 is an important cytokine with anti-inflammatory func-
tions [28]. For example, in mouse models of acute kid-
ney injury, IL-10 administration has a beneficial effect by
inhibition of leukocyte infiltration and inflammatory renal
cell death [29]. It also influences T cells by attenuating
proliferation of CD4+ T cells and their cytokine production
[30]. The tissue-resident dendritic cells (DCs) also promote
the resolution of inflammation by producing pentraxin-3
(PTX3) which inhibits P-selectin on the vascular endothelial
cells and thus inhibits immune cell recruitment to sites of
injury [31–33]. Moreover, neutrophils released the prestored
PTX3 in the early phase of acute myocardial infarction

















Figure 1: The role of the innate immune system in regaining tissue
homeostasis. An injury disturbs the tissue homeostasis and activates
the innate immune system leading to the recruitment of several
immune cells at the site of injury. These immune cells secrete
cytokines, growth factors, and enzymes to establish an inflammatory
milieu. They also secrete anti-inflammatory and proregenerative
cytokines to promote resolution of inflammation as well as tissue
repair. A transient inflammation is often helpful to get rid of the
cause of the tissue injury and return to homeostasis. However, an
uncontrolled or persistent inflammation promotes tissue remodel-
ing and fibrosis.
proinflammatory response [34], whereas PTX3 also aggre-
gated with histones and protected from histone-mediated
endothelial cytotoxicity in sepsis [35, 36]. Furthermore, PTX3
suppressed complement dependent inflammation as well as
reduced tumor infiltration by macrophages [37].
Group 3 ILCs gets activated and produces IL-22 after
an intestinal epithelial injury suggesting that inflammation
can override injury by promoting tissue regeneration [38].
Moreover, IL-22-producing ILCs prevented systemic inflam-
mation during chronic diseases by promoting anatomical
containment of lymphoid-resident commensal bacteria [39].
Similarly, the redox modification of high mobility group box
1 (HMGB1), a danger associated molecular pattern (DAMP)
released after tissue injury as well as by macrophages and
monocytes, regulated its proinflammatory functions during
the resolution of inflammation and prevented excessive
acetaminophen-induced hepatic injury [40, 41]. Together,
immune cells, as well as mediators released by them, promote
resolution of inflammation in order to reestablish the home-
ostasis after injury.
3. Tissue Regeneration and Repair
The immune system is instrumental in supplying growth
factors and cytokine signals that orchestrate tissue repair. For
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example, the tissue-resident macrophages originated from
yolk sac-derived erythromyeloid progenitors that possess
the capacity to self-replenish [42, 43], while bone-marrow-
derived circulating monocytes differentiate into tissue ma-
crophages [44], but both are activated during injury. Blood-
derived young monocytes/macrophages have enhanced
remyelinating activity compared to old macrophages in the
central nervous system [45]. Although M2 macrophages are
the main driver of the resolution of inflammation, tissue
repair, and scar formation, the M1 macrophages clear
cellular debris in order to prevent the persistence of toxic
and immunogenic material at the site of injury. Therefore,
depletion of M1 macrophages resulted in impaired healing
and regeneration after myocardial as well as skeletal muscle
injuries [46, 47]. In addition, M1 macrophages also activated
proliferative myogenesis via IL-6, TNF-𝛼, and IL-1𝛽 whereas
M2 macrophages supported myogenic differentiation via
TGF-𝛽 production during skeletal muscle regeneration
[47, 48].
Moreover, infiltrating eosinophils secreted IL-4 to induce
proliferation of fibro/adipocyte progenitor cells, which pro-
moted clearance of necrotic debris and skeletal muscle
regeneration [49]. The CXCL12-CXCR4 pathway regulates
the recruitment of progenitors, the unipotent proliferative
cells with a capacity of self-renewal [50], at the site of
injury [51]. Other mediators of the innate immune system
that induced progenitor cells proliferation and regeneration
include leukotriene C4, which activated radial glial cell
proliferation and neurogenesis either upon or without an
injury [52], oncomodulin derived from neutrophils, and
macrophages which promoted the optic nerve regeneration
[53, 54]. Furthermore, macrophages derived Wnt suppressed
Notch signaling and thus regulated the fate of hepatic as well
as renal progenitor cells after liver and kidney injury, respec-
tively [55, 56]. Macrophage-derived Wnt7b also stimulated
epithelial responses and, thus, regarded critical for kidney
repair and regeneration [57]. In the acidic tissue environ-
ments after skin, liver, and lung injury and arterial throm-
bosis, neutrophils and macrophages derived PTX3 promoted
remodeling of the fibrin-rich inflammatory matrix ensuring
normal tissue repair [58]. In addition, the complement
system is also instrumental in promoting tissue repair and
regeneration by inducing growth factors as well as disposal of
dead cells [23]. In particular, C3a and C5a activated NF-𝜅B/
STAT-3 and enhanced hepatocyte regeneration after liver
injury [59]. Recent reports showed that the delayed postin-
jury administration of C5a inhibited caspase-3 mediated
neuron apoptosis leading to improved regeneration and
functional recovery after murine spinal cord injury [60], as
well as administration of C3a retina regeneration via STAT-3
activation in the progenitor cells present in the eye [61].
Apoptotic cells released after tissue injury promoted
angiogenic properties of macrophages by releasing prostagl-
andin E2, which induced endothelial-derived progenitors
to angiogenesis and vascular repair during skeletal muscle
regeneration [62–64]. In addition, proliferation and differ-
entiation of renal progenitor cells were also enhanced by
the Toll-like receptor- (TLR-) 2-agonistic DAMPs released
after tissue injury [65–67]. Several recent data suggests
additional mechanisms of DAMP-driven tissue regeneration.
For example, TLR4-agonistic DAMPs activated the inter-
stitial mononuclear phagocytes to secrete a proregenerative
cytokine IL-22 [68, 69] to promote tubular cell regeneration
after injury by activating the JAK/STAT3 and ERK1/2 sig-
naling pathway [68, 70]. Group 3 ILCs also produced IL-22
after an intestinal injury to promote the intestinal stem cell-
mediated epithelial regeneration [71]. IL-22 mediated pro-
tection and regeneration were also observed in experimental
models of hepatic, pancreatic, and thymic injuries [72–75].
In addition, a mast cell-specific tryptase, mouse mast cell
protease (mMCP) 6, directly cleaves fibronectin and collagen
IV and, therefore, suppressed scars and promoted functional
recovery after spinal cord injury [76]. Platelets contributed
to liver regeneration by secreting serotonin in mice as well
as humans [77, 78]. Group 2 ILCs also promoted lung-tissue
homeostasis after infection with influenza virus by producing
a growth factor Amphiregulin [79]. After an injury to skeletal
muscles, IL-33 recruited a special population of regulatory T
cells (Tregs) to the injured muscles that produced Amphireg-
ulin and improved the muscle repair [80–82]. Together, this
illustrates that the innate immune system and its mediators
do not only contribute to the immune injury but also to the
immune-mediated repair or regeneration after injury as a part
of a danger control response [10, 83] (Figure 2).
4. Tissue Remodeling and Fibrosis
Thewell-defined chronology of inflammatory events is essen-
tial for optimal repair. However, an overactivated immune
response leads to tissue remodeling rather than tissue regen-
eration, which is clinically termed as tissue fibrosis. Fibrosis
is characterized by excess deposition of extracellular matrix
(ECM) due to the accumulation and activation of fibroblasts
and myofibroblasts. Inflammatory cells of the immune sys-
tem, as well as factors released by them, facilitate fibrosis. For
example, tissue injury is always followed by altered vascular
permeability to enhance the neutrophils recruitment to the
site of injury. The delayed clearance of neutrophils from the
site of injury further exacerbates the injury [84]. Neutrophils
count is in fact used as a prognostic marker for cardiac
remodeling [85]. Neutrophils are known to increase oxidative
stress as well as release a number of enzymes like matrix
metalloproteinases (MMPs), elastase, and cathepsins which
contribute significantly to the process of fibrosis [86–88].
Apart from neutrophils, platelets can also respond to the state
of infection or inflammation through activation of TLRs [89,
90]. The factors derived from platelets, for example, platelet-
derived growth factor (PDGF), is a potent chemotactic agent,
whereas TGF-𝛽 drives fibroblast proliferation and activation
[91]. Moreover, the factors involved in coagulation can also
contribute significantly to fibrosis, for example, factors VII,
IX, and X [92–94]. The coagulation system and complement
system are linked very closely, often involving a cross talk,
to maintain the tissue homeostasis [23, 95]. For example, in
the absence of C3, thrombin replaces the C3 dependent C5
convertase and directly cleaves C5 to generate the biologically
active C5a [96], which induced fibrosis in lungs, liver,
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Figure 2: Mediators of innate immune system in regaining tissue homeostasis. Innate immune cells secrete several cytokines, growth factors,
and enzymes, which promotes either resolution of inflammation and tissue repair/regeneration or tissue remodeling/fibrosis. PTX3: pentraxin
3, ROS: reactive oxygen species, IL: interleukin, TGF: transforming growth factor, MMP: matrix metalloproteinase, TIMP: tissue inhibitor of
matrix metalloproteinase, TNF: tumor necrosis factor, MIP: macrophage inhibitory protein, MBP: major basic protein, mMCP: mouse mast
cell protease, and PDGF: platelet-derived growth factor.
pancreas, and kidney after injury [97–100]. In addition to
C5a, C3a has also been implicated in renal fibrosis [101].
Other cells of the innate immune system, for exam-
ple, eosinophils and mast cells, also contribute to fibrosis.
Eosinophils produce TGF-𝛽, major basic protein (MBP)-1,
eosinophilic peroxidase as well as granule proteins, and lyso-
somal hydrolytic enzymes which are implicated to be a part
of fibrosis process [102].Mast cells produce various proteases,
vasoactive factors like histamine, cytokines, and TGF-𝛽
during the tissue injury and fibrosis [103]. IL-4, one of the
major products of mast cell activation, contributes to the
cardiac fibrosis [104]. Moreover, mast cell deficient mice are
protected against pulmonary as well as cardiac fibrosis [105,
106]. Among the various immune cells, the macrophages are
essential for efficient wound healing [107–111]. Macrophages
are the main source of MMPs and tissue inhibitor of met-
alloproteinases (TIMPs) [109, 112, 113]. The balance between
MMPs and TIMPs is crucial for maintaining the composition
of ECM. Apart from MMPs and TIMPs, macrophages also
contribute to the production of TGF-𝛽, the most significant
factor involved in fibrosis [114]. TGF-𝛽 regulates fibroblast
activation, differentiation, and proliferation [115]. It also
upregulates ECM genes and suppresses genes associated with
MMPs, thus causing increased deposition of matrix. TGF-𝛽
promotes collagen synthesis and the expression of profibrotic
genes such as type I collagen and connective tissue growth
factor (CTGF) [15, 116]. Furthermore, TGF-𝛽 is also an
anti-inflammatory factor; therefore, its early inhibition is
associated with increased mortality, increased chemokine
expression, and leukocyte infiltration while its inhibition
during the resolution phase resulted in improved survival
and reduced tissue fibrosis [117–122]. Activated macrophages
induce production of various cytokines and factors like
interleukins (e.g., IL-1𝛽) and TNF-𝛼, which drive further
inflammation and fibrosis by enhancing ECM production as
well as upregulating expression of TGF-𝛽 [123, 124]. Deple-
tion of macrophages during the early phase of tissue injury
ameliorated fibrosis, while delayed depletion of macrophages
during the resolution phase exaggerated fibrosis with persis-
tence of profibrotic cellular and matrix components [110, 111,
125]. Although recent studies demonstrated an association
between macrophages derived PTX3 and tissue fibrosis in
nonalcoholic fatty liver disease as well as in lung fibrosis,
whether PTX3 causes fibrosis or not is still unclear [126, 127].
Along with macrophages, DCs are the primary determi-
nants of the cytokine and chemokine milieu during fibroge-
nesis [128, 129]. For example, IL-6 and TNF-𝛼 produced by
DCs have pleiotropic effects on liver fibrosis [128]. Further-
more, they also activated NK cells to produce TNF-𝛼 and,
therefore, elevate the inflammatory environment in fibrotic
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livers [128]. Group 3 ILCs promoted bleomycin-induced
pulmonary fibrosis by secreting IL-17 [130, 131], whereas IL-
25 induced expansion of the group 2 ILCs within the lungs,
which promoted pulmonary fibrosis via IL-13 dependent
mechanism [132]. Together, the innate immune system and
its mediators contribute to tissue remodeling and fibrosis
(Figure 2).
5. Conclusions and Future Perspectives
Maintaining tissuemorphology is essential tomaintain tissue
function, that is, homeostasis. An injury or damage affects
the structural integrity of the tissue implying a loss of tissue
function, and, therefore, the structural and functional recov-
ery, that is, regaining homeostasis after injury, is the ultimate
goal. The inflammatory mediators of the innate immune
system are important regulators of tissue homeostasis. They
modulate tissue environments at all phases of the homeostatic
imbalance, for example, promotion as well as the resolution
of inflammation, tissue regeneration, and tissue remodeling/
fibrosis.
Our understanding of inflammation biology has
increased over the last few decades and has gone far beyond
the basic concept of inflammation that was originally
introduced by Hippocrates. The advancements in micro-
scopic as well as flow associated cell sorting (FACS) tech-
niques have allowed us to understand and redefine the
“inflammation.” This progress has also raised several ques-
tions, for example, what are the molecules or signals that
regulate the function of the innate immune cells, what are
the critical mechanisms that regulate the balance of different
populations of these cells in the specific phase after injury,
and how to modulate the behavior as well as balance of these
cells in each phase after injury to enhance tissue regeneration
and reduce fibrosis. The advancements in the new genomic
technologies such as CRISPR-Cas9 have transformed the
field of immunology research and will certainly speed up
novel discoveries in regulatory and signaling components of
inflammation biology.
The newly obtained knowledge will translate into novel
therapeutic strategies for inflammatory diseases. For exam-
ple, recent studies have identified proinflammatory and
proregenerative potential of a cytokine IL-22 and a regulatory
oncoprotein murine double minute- (MDM-) 2 in the patho-
genesis of ischemic renal injury (IRI) and have demonstrated
the therapeutic potential of recombinant IL-22 and MDM-2
inhibitor, nutlin-3a, in IRI and other inflammatory diseases
[68, 133–135]. Moreover, other studies have identified a
pattern recognition molecule PTX3 as a potential target for
therapeuticmanipulation in damaged tissues as well as a vari-
ety of diseases [37, 58]. Therefore, in-depth understanding
of the functions of inflammatory cells as well as mediators
of inflammation will be instrumental in the identification of
novel therapeutic targets and treatment strategies for several
inflammatory diseases. As written by a Scottish surgeon in
1974 “Inflammation in itself is not to be considered as a
disease but as a salutary operation consequent to some
violence or some disease” [136].
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